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Abstract
Objectives: The prevalence, clinical characteristics and
prognosis of pleural effusions (PEs) associated with
ovarian cancer (OC) have seldom been addressed system-
atically, as in the current investigation.
Methods: All records of consecutive women with a newly
diagnosed OC in our institution over a 13-year period were
retrospectively reviewed. Features of PEs on CT scans,
pleural fluid analyses, need for definitive therapy of PEs,
and the influence of PEs on the overall survival (OS) and
progression-free survival (PFS) were evaluated.
Results: PEs were observed in 81 (43%) of 189 women
with OC, either at presentation of cancer (55 patients) or
during the course of the disease (26 patients). The causes
of PEs were malignancy (55.5%), unknown (37%), or
surgery-related (7.4%). The sensitivity of the cytologic
diagnosis of malignant PEs was 79.1%. Sixty percent of
malignant PEs required pleurodesis or indwelling
pleural catheters for symptomatic relief. The presence of
ascites strongly predicted PE development (odds ratio
43.2). Women with PEs fared much worse compared with
those without PEs, in terms of OS (26.7 vs. 90.4 months),
PFS (9.8 vs. 55.3 months) and tumor recurrences (86.4 vs.
43%). In multivariate analyses, PE remained as a rele-
vant independent variable associated with poor
outcome (hazard ratio 9.73 for OS, and 3.87 for PFS).
Notably, PEs small enough to preclude tapping, and
thus of unknown origin, had a similar bad prognosis as
malignant PEs.
Conclusions: OC patients with PEs experience decreased
survival, including thosewith trace effusions not amenable
to tapping.
Keywords: indwelling pleural catheter; ovarian cancer;
pleural effusion; pleurodesis; survival.
Introduction
Ovarian cancer (OC) encompasses a heterogeneous group
of malignancies, over 90% of which are of epithelial origin
[1]. Fewer than half of patients with OC survive beyond
five years after diagnosis, partly because more than 70%
are discovered in an advanced disease stage [1]. OCwas the
sixth leading cause of 840 tapped malignant pleural effu-
sions (MPEs), after lung, breast, unknown primary, he-
matological, and gastrointestinal tumors [2]. However, it
ranks third if only women are being considered [3]. OC
often initially manifests with a pleural effusion (PE). In a
retrospective analysis of 32 consecutive OC women with
MPE, the effusion was among the presenting symptoms of
cancer in 24 (75%) cases [4].
Few studies have addressed the prognostic signifi-
cance of PEs in the context of specific primary malig-
nancies. For example, PEs, including those too small to be
aspirated, have been found to be an independent predictor
of poor survival in lung cancer [5] and diffuse large B-cell
lymphoma [6]. The only two such studies conducted in OC
provided a partial view of the problem because they
included a very select population. One analyzed a small
number of patients with cytology-proven MPEs who un-
derwent optimal abdominopelvic cytoreductive surgery
[7], while the other focused on PEs detected before a pri-
mary debulking surgery for advanced cancer grades [8]. In
the current investigation we aimed, for the first time, to
systematically analyze the etiology, clinical characteris-
tics, and outcomes of PEs at any OC stage, as well as the
influence they may have on overall survival (OS) and
progression-free survival (PFS).
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We retrospectively reviewed all consecutive patients who were newly
diagnosed with OC from January 2007 to December 2019 at our aca-
demic teaching hospital. The study was approved by the local Ethics
Committee (CEIC No. 1965).
Data collection
Electronic medical records were queried for the following variables: age
at diagnosis of cancer, serum concentrations of CA125 at tumor detec-
tion, tumorhistology, identificationofpotential OC-susceptibility genes,
presence and characteristics of PE (side and volume according to a
previously reported formula) [9] on computed tomography (CT) at any
time from the diagnosis, identification of pleural thickening ≥3mmand/
or nodularity, ascites, or anymetastatic site on CT imaging, biochemical
and cytological pleural fluid (PF) data when available, Easter Cooper-
ative Oncology Group (ECOG) performance score and International
Federation of Gynecology and Obstetrics (FIGO) staging system at the
first encounter, treatments received (optimal or suboptimal cytoreduc-
tive surgery, chemotherapy, antiangiogenesis therapy, poly ADP-ribose
polymerase [PARP] inhibitors), recurrence of disease on the basis of
radiological criteria, need for pleural interventional procedures (thera-
peutic aspirations, pleurodesis, tunneledpleural catheters), OSandPFS.
For bilateral PEs, the effusion with the greater size was recorded.
Diagnostic criteria for pleural effusions
A PE was categorized as malignant if malignant cells were detected
upon cytological examination of PF (whether smears or cell blocks) or
biopsy specimens. A diagnosis of probable MPE was based on the
demonstration of a cytology-negative exudate, after reasonably ruling
out benign causes of fluid accumulation. Other etiologies of PEs were
defined using well-established clinical criteria [10]. Untapped PEs
were classified as being of uncertain origin, unless clearly ascribed to a
postoperative complication (postsurgical PEs). Interpretation of chest
and abdominal CT imagingwas done by an expert radiologist whowas
blinded to clinical data, other than that the patient had OC.
Statistical analysis
Continuous and categorical variables were expressed as medians
(quartiles 25th and 75th) and percentages, respectively. For between-
group comparisons, either the Chi-square, Kruskal–Wallis or Mann–
Whitney U tests were used, whichever was appropriate. A logistic
regression analysis was performed to determine predictors of PE
development.OSwascalculated fromdate ofOCdiagnosis until death or
last follow-up. PFS was defined as the time from initiation of any active
oncologic treatment to the occurrence of progressive disease, relapse, or
death. The Kaplan–Meier method and Cox proportional hazard regres-
sion model were used for calculation of survival over time, while sur-
vival differences were analyzed using the log-rank test. The optimal
cutoff values for PE size (expressed in mL) and preoperative CA 125 (U/
mL)weredeterminedby receiver operating characteristic curveanalysis,
looking for a specificity of 85%topredict death or cancer recurrence. A p
value <0.05 was considered statistically significant in all analyses. Cal-
culations were done using SPSS version 24.0 statistical software.
Results
Study population
A total of 189 women with a median age of 63 years (range,
28–93 years) were diagnosed with OC during the 13-year
study period. Twenty-six (26%) of 99 tested patients carried
pathogenic mutational variants, mostly BRCA1 and/or
BRCA2 (17%). Histological types, FIGO disease stages and
ECOG performance status at diagnosis, and therapeutic
approaches are shown in Table 1. OC was located on the
right side in 25% of the cases, on the left in 30%, and
bilaterally in 45%. Standardized surgery was attempted in
157 (83%) women, though optimal abdominopelvic cytor-
eduction was achievable in 78 (50%).
Characteristics of pleural effusions
At presentation of OC, 55 (29%, 95%CI 23–36%) patients
showed PEs on CT images. Twenty-six additional women
developed PEs during the course of the disease following a
median of 5.2 months (six days–30.6 months) from tumor
diagnosis. Thus, the overall prevalence of PEs was 42.8%
(81 of 189 patients, 95%CI 36–50%). Some differential
features of OC women with and without PEs are displayed
in Table 1. Notably, ascites was much more prevalent in
those with PEs (96.3 vs. 46.3%, p<0.001). Pleural nod-
ularity or thickening on CT scans, a radiological sign sug-
gestive of malignancy, was invariably associated with the
presence of PEs, in particular MPEs and, less often, PEs of
uncertain cause. Moreover, women with PEs developed
recurrent OCmore frequently (86.4 vs. 43.1%, p<0.001) and
in a shorter time period from cancer diagnosis (12.6 vs.
20.8 months, p=0.003) than those without PEs.
In a multivariate analysis, which included the statisti-
cally significant variablesof theunivariate analysis (Table 1),
independent risk factors for the occurrence of PEs in OC
patients were the existence of ascites (odds ratio [OR] 43.2,
95%CI 5.5–337.8), extra-pleural recurrences (OR 4.4, 95%CI
1.6–12.3) and peritoneal metastases (OR 3, 95%CI 1.2–7.2).
PEs were bilateral in 43 cases (53%), right-sided in 21
(26%) and left-sided in 17 (21%). The etiologies of the 81 PEs
were definitely malignant (36, 44.4%), probable malignant
(9, 11.1%), uncertain (30, 37%) andbenign (six postsurgery,
7.4%). The six PEs in women with FIGO stages I and II were
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related to surgery (n=2), or undefined causes (n=4). The
median volume of PEs was significantly higher in the ma-
lignant group (400 mL [200–1,200] vs. 100 mL [65–225],
p<0.001). None of the subjects with PEs of uncertain cause
underwent thoracentesis, usually because of the small
quantity of fluid (median 100 mL, quartiles 50–500). PF
was eventually analyzed in 45 (55.5%) patients. All MPEs
were exudates, with a lymphocyte-predominance in 93%of
the cases, and the overall cytologic yield for the examina-
tion of two separate fluid specimens (smears and/or cell
blocks) was 79.1% (72.1% if only one specimen had been
submitted). Of the 45 subjects with MPEs, 30 (66.7%)
Table : Baseline characteristics of OC patients.





Age, years  (–)  (–)  (–) <.
Carriers of genetic mutations / (.%) / (.%) / (.%) .
CA in serum at diagnosis, U/mLb  (–,)  (–,)  (–) <.
Pleural nodularity and/or thickening on CTc  (%)  (%)  (%) <.
ECOG performance status
 / (.%)  (%) / (%)
 / (.%)  (%) / (%) .
 / (.%)  (%) / (%)
 / (.%)  (%) / (%)
FIGO stage
I  (%)  (%)  (%)d
II  (%)  (.%)  (%) <.
III  (%)  (.%)  (%)
IV  (%)  (%)d  (%)
Histological type
High-grade serous carcinoma  (%)  (%)  (.%)
Low-grade serous carcinoma  (%)  (%)  (.%)d
Endometrioid  (.%)  (.%)  (.%)d .
Clear cell  (.%)  (.%)  (.%)
Mucinous  (.%)  (%)  (.%)
Non-differentiated  (.%)  (%)d  (.%)
Others  (.%)  (.%)  (.%)
Metastatic locations
Peritoneal  (.%)  (.%)  (%) <.
Ascites  (.%)  (.%)  (.%) <.
Lymph nodes  (.%)  (.%)  (.%) .
Liver  (.%)  (.%)  (%) .
Lung  (.%)  (.%)  (.%) .
Bone  (.%)  (.%)  (%) .
Brain  (%)  (%)  (.%) .
Soft tissue  (%)  (%)  (.%) .
Spleen  (.%)  (.%)  (.%) .
Treatments
Surgery  (%)  (%)  (%) .
Optimal cytoreductive surgery  (.%)  (.%)  (.%) .
Adjuvant chemotherapy / (%) / (%) / (%) <.
Neoadjuvant chemotherapy  (%)  (%)  (%) <.
Angiogenesis inhibitors  (%)  (.%)  (%) .
PARP inhibitors  (%)  (.%)  (.%) .
Palliative care  (.%)  (.%)  (.%) .
Recurrent disease / (%) / (.%) / (%) <.
Deaths  (.%)  (.%)  (%) <.
ap-Value for the comparison of OC with and without pleural effusions. bData on serum CA was available in  patients ( with and 
without pleural effusions). cThe etiologies of pleural effusions associatedwith pleural nodularity and/or thickeningweremalignancy (n=) and
unknown (n=). dSignificantly superior than the comparator group. CT, computed tomography; ECOG, Easter CooperativeOncologyGroup; FIGO,
Federation of Gynecology and Obstetrics; OC, ovarian cancer.
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required one or more palliative pleural procedures (18
therapeutic thoracentesis, 14 bedside pleurodesis, and 13
indwelling pleural catheters).
Survival
At the end of the study, 112 (59%) patients had died and
the median follow-up time for the remaining 77 was 59.1
(25.8–80.1) months. Median OS for the entire cohort
was 48.5 months (95%CI 33.8–63.2). Women with PEs sur-
vived less than those without PEs (26.7 months, 95%CI 22–
31.3 vs. 90.4 months, 95%CI 46.2–134.6; p<0.001). Specif-
ically, OS was significantly lower in the subgroup of patients
with either MPEs (24.2 months, 95%CI 17.5–30.9) or PEs of
uncertain origin (27.4months, 95%CI 18.3–36.5) as compared
to the non-PE group (p<0.001) (Figure 1). Although there was
a trend toward a better OS in women whose PEs appeared
during the disease course (34.5 months, 95%CI 25.4–43.5) in
contrast to those with PEs at the time of OC diagnosis
(20.8 months, 95%CI 13.9–27.7), it did not reach statistical
significance (p=0.296).
A multivariate analysis using the Cox regression model
was performed, after entering the following variables as
potential prognostic factors: age, serumCA125 ≥ 1,200U/mL
at diagnosis, FIGO stage, ECOG, OC histological type,
metastatic pattern, presence of PEs, volume of PEs >250mL,
pleural nodularity and/or thickeningonCTscans, ascites, as
well as surgical therapy and its results (optimal or subop-
timal cytoreduction). As shown in Table 2, the presence of
PE was one of the strongest predictors of decreased survival
(hazard ratio [HR]9.73). Exclusionof the six postsurgical PEs
for the calculations did not change results (data not shown).
Median PFS of the study population was 21.9 months
(95%CI 18.3–25.6). Itwas lower in thePE cohort (9.8months,
95%CI 8.4–11.6) than in thenon-PEgroup (55.3months, 95%
CI 15.6–95; p<0.001) (Figure 2). MPEs and PEs of uncertain
etiology exhibited similar PFS (10 months, 95%CI 8.7–11.3
vs. 8.1, 95%CI 5.7–10.5; p=0.593) (Figure 2). Therewas also a
nonsignificant tendency toward a better PFS when PEs
developed during follow-up rather than being discovered at
the time of OC diagnosis (12.6 months, 95%CI 8–17.2 vs.
8.1 months, 95%CI 5.5–10.6; p=0.081).
Figure 1: Median overall survival of ovarian cancer patients
according to the pleural effusion status.
OS, overall survival; MPE, malignant pleural effusion; PE, pleural
effusion.
Table : Cox proportional hazard models assessing overall survival
of OC patients.
Variable Adjusted HR (%CI) p-Value
Presence of PE . (.–.) <.
No surgical treatment . (.–.) <.
Peritoneal metastases . (.–.) .
PE volume > mL . (.–.) .
Suboptimal cytoreductive surgery . (.–.) <.
CI, confidence interval; HR, hazard ratio; OC, ovarian cancer; PE,
pleural effusion.
Figure 2: Median progression-free survival of ovarian cancer pa-
tients stratified for pleural effusion status.
MPE, malignant pleural effusion; PE, pleural effusion; PFS,
progression-free survival.
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The multivariate Cox regression model showed that,
for the same variables as those previously mentioned for
the OS statistical model, PEs were included among the
most significant predictors of a poor PFS (HR 3.87)
(Table 3).
Discussion
To our knowledge, this study represents the first simulta-
neous evaluationof the prevalence, clinical andPF features,
and prognosis of PEs in women with OC. PEs occurred in
43% of the cases, using CT as the reference standard, and
independently contributed to mortality and PFS.
Most OCwere diagnosed at FIGO stages III (51%) and IV
(30%). Since PE with positive cytology defines FIGO stage
IVA, reasonably the majority of detected PEs fell into the
advanced stages III (39.5%) and IV (53%). The overall
prevalence of PEs in OC (43%) was quite similar to that
reported for other primary tumors that metastasize to the
pleura, such as lung cancer (40%) [5] or diffuse large B-cell
lymphoma (30%) [6]. Pleural nodularity or thickening
characterized 27% of MPEs in OC women, which is some-
what lower than the 43% general prevalence of these spe-
cific radiological signs in pleural malignancies [11].
However, the potential malignant nature of PEs that were
classified as being of uncertain origin cannot be excluded
(16.7% of which exhibited pleural nodules and/or thick-
ening). Also, in the context of an OC, it was found that the
larger the accompanying PE, the more likelihood of being
malignant. This is not surprising, considering that malig-
nancy accounts for more than half of large or massive PEs
[12]. In a study of 16 OC patients with MPEs and 22 with
nonmalignantPEs,moderate to large amounts ofPF (81.3 vs.
9.1%) and pleural nodules (50 vs. 0%), along with supra-
diaphragmatic lymph node enlargement (75 vs. 9.1%) pre-
dominated in the former group and, therefore, these CT
signs increased the probability for a PE to be malignant [13].
The yield of PF cytological examinations seems to be
particularly high in MPEs secondary to OC as compared to
other tumor types. While the overall sensitivity of PE
cytology for identifying malignancy is around 55% [14], it
was found this percentage reached 79% in our cohort of OC
women, which is in line with other reports. For example, in
four series comprising 27, 31, 38, and 96 MPEs due to OC,
the respective PF cytological yields were 83, 84, 94.7, and
78% [15–18], though no information on the number of fluid
specimens processed and the way they were examined
(whether smears and/or cell blocks) were provided.
Another point was that MPEs in OC were symptomatic
enough to require definitive pleural procedures, either
bedside pleurodesis or insertion of an indwelling pleural
catheter, in 60% of the cases. This percentage compares
with that observed in amulticenter cohort of 537MPEs from
a variety of tumor types (OC representing only 5.8% of the
cases), where 288 (53.6%) eventually needed to be treated
with pleurodesis and/or indwelling pleural catheters [19].
The mechanism of metastatic pleural involvement in
OC is speculative and probably includes one or more of the
following: a) invasion from an affected contiguous dia-
phragm, b) migration of tumor cells from the peritoneal
cavity to the pleural space through small diaphragmatic
defects, and c) hematogenous spread. The relevance of the
first two potential ways of cancer dissemination was sup-
ported by the finding of ascites and peritoneal metastases
(which encompasses peritoneal diaphragmatic implants)
as independent predictors of PE development.
Our survival analysis showed that women with PEs
(particularly PEs of at least 250 mL), had worse OS and PFS
than those without PEs after adjustment for confounders. A
pair of prior studies cast a sobering light on the prognostic
impact of PEs in OC women. In an earlier retrospective study,
21 OC patients with stage IVA (due to MPEs), who underwent
tumordebulking to less than 1 cmof residual disease followed
by platinum-based chemotherapy, had a shorter time to
recurrence (12 vs. 21 months, p=0.04) and decreased OS (30
vs. 58 months, p=0.016) compared to 76 similarly treated
patients with stage IIIC [7]. However, CT scans were not used
for staging and, therefore, the existence of undetected intra-
thoracic disease could not be excluded. In a second study
from the same institution, the preoperative CT images of 172
stage III and 31 stage IV OC women undergoing primary
cytoreduction were retrospectively evaluated [8]. The preva-
lence of PEs at diagnosis (62 patients, 30.5%) was almost
identical to that observed in our study. However, only 19
(30%)were tapped,ofwhich 16weredeemed tobemalignant.
In both stages III and IV the presence of PEs occupying one-
third or more of the hemithorax was independently associ-
ated with worse OS in a multivariate analysis (HR=2.27) [8].
A novel finding of our study is that even trace effusions
not amenable to tapping confer a survival disadvantage,
Table : Cox proportional hazard models assessing progression-
free survival of OC patients.
Variable Adjusted HR (%CI) p-Value
Lung metastases . (.–.) <.
No surgical treatment . (.–.) <.
Presence of PE . (.–.) <.
Suboptimal cytoreductive surgery . (.–.) <.
CI, confidence interval; HR, hazard ratio; OC, ovarian cancer; PE,
pleural effusion.
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with a differential life expectancy of 63 months as compared
to patients without PEs. It can be hypothesized that many of
these minimal effusions are actually MPEs which go unno-
ticed due to the difficulty of performing conventional diag-
nostic procedures. It should be stressed that an accurate
identification of the presence and extent of pleural involve-
ment, though paramount for determining prognosis and
selecting appropriate treatment, is difficult by noninvasive
means. The true pleural status revealed during video-
assisted thoracoscopic surgery (VATS) do not always corre-
late with the CT features considered suggestive of pleural
malignancy (i.e., thickeningand/ornodularity) [20], norwith
the PF cytology results [18–21]. For instance, in a series of 44
advanced OC patients who underwent VATS, 10 and 16 had
pleural nodules and pleural thickening suspicious of ma-
lignancy on preoperative CT scans, respectively [20]. How-
ever, thoracoscopic biopsies did not confirm pleural tumor
invasion in two and six of these cases. In a recent study,
VATS was performed on 100 women with advanced OC and
PEs occupying one-third or more of the pleural cavity [18].
Macroscopic pleural disease was identified in 70% and was
independently associated with elevated death risk. Interest-
ingly, 29% of patients with negative PF cytology had gross
macroscopic disease at VATS [18]. Conversely, no gross
pleural disease is seen during VATS procedures in around
25% of OC patients with positive PF cytology [21]. These data
support the indication of VATS in all OC women with mod-
erate to large PEs in order to confirm macroscopic pleural
disease that may impact management [18]. Currently, it has
not been established whether bulky pleural involvement is
present in OC women with small PEs and if VATS could be
beneficial in these patients.
Our study has several limitations. First, our cohort was
sourced from a single institution and spanned a relatively
long-period of time during which therapeutic approaches
have varied. Second, the sample size was moderate and the
study design retrospective, though there were very little
missing data. Third, our reference standard for some MPEs
(those labeled as probable MPEs) was imperfect, but widely
accepted inmedical literature. Finally, 44% of PEs could not
be analyzed due to their small volume which, on the other
hand, reflects daily clinical practice. Yet demonstration of
the poor outcome of these minimal PEs is a relevant fact.
In summary, PEs are frequently encountered in OC
women and portend a poor prognosis, even those of such a
small size that a diagnostic thoracentesis cannot be per-
formed safely. Nearly two-thirds of MPEs associated with OC
need definitive pleural procedures, either pleurodesis or
indwelling pleural catheters, for symptomatic control.
Whether minimal PEs harbor undiagnosed pleural involve-
ment should be explored in future investigations.
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